Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Period	Debt/Equity
2015-12-31	0.41
2016-12-31	0.43
2017-12-31	0.49
2018-12-31	0.56
2019-12-31	0.66
2020-12-31	0.83
2021-12-31	0.50
2022-12-31	0.88
2023-12-31	0.78
2024-12-31	0.40

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALKS	$34.84	+0.00%	2.49M
3
4
5

Alkermes plc (ALKS) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Alkermes plc Data in Excel

More ALKS Financial Data